Cyclacel regains compliance with NASDAQ minimum bid price listing requirement Cyclacel Pharmaceuticals announced that it has received notification from NASDAQ that it has regained compliance with the minimum bid price rule for continued listing on The NASDAQ Global Select Market. The letter received noted that as of Sept. 11, the company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the company has regained compliance with Listing Rule 5450a1 and the matter is closed.
News For CYCC From The Last 14 Days
Check below for free stories on CYCC the last two weeks.
Subscribe for More Information